Mangalam Drugs and Organics Limited



Regd. Office: Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001. © 91-22-22616200 / 6300 / 8787 ⊕ 91-22-22619090 ● CIN: L24230MH1972PLC116413

REF: MDOL/CS-SE/2022-23/036

January 13, 2023

To, Listing Department BSE Ltd 1st Floor, New Trade Wing, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001

Listing Department
National Stock Exchange of India
Limited
"Exchange Plaza" 5th Floor

"Exchange Plaza", 5th Floor, Plot No. C-1, Block G, Bandra - Kurla Complex, Bandra(E), Mumbai - 400 051

Scrip Code: 532637 Symbol: MANGALAM

Sub: Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 - Reconciliation of Share Capital Audit Report for the quarter ended December 31, 2022

Dear Sir/Madam,

Pursuant to Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed the Reconciliation of Share Capital Audit Report for the quarter ended December 31, 2022.

We request your good office to kindly take the above certificate on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For Mangalam Drugs & Organics Limited

Govardhan M. Dhoot Managing Director DIN:01240086



RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

UNDER REGULATION 76 OF SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS, 2018

To,

M/s. Mangalam Drugs & Organics Limited (Hereinafter referred to as Company)

CIN: L24230MH1972PLC116413

Address: 3rd Floor, Rupam Building, 239, P.D' Mello Road, Near G.P.O., Mumbai – 400001,

Maharashtra, India

Dear Sirs / Madam,

We have examined the relevant books, registers, forms, documents and papers produced before us by M/s. Mangalam Drugs & Organics Limited ('the company') and its Registrars and Transfer Agent M/s. Link intime India Pvt. Ltd., in respect of Reconciliation of Share Capital Audit as per the Regulation 76 of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. To the best of our knowledge and according to the information and explanations given to us and as shown by the electronic records examined by us, we certify the following:

1.	For Quarter Ended	Ī	December 31, 2022
2.	ISIN	:	INE584F01014
3.	Face Value	:	Rs. 10/- each
4.	Name of the company	:	Mangalam Drugs and Organics Limited
5.	Registered Office Address	:	3 rd Floor, Rupam Building 239, P. D'mello Road Mumbai -400001, Maharashtra, India
6.	Correspondence Address		3 rd Floor, Rupam Building 239, P. D'mello
О.	Correspondence Address	<u> </u>	Road Mumbai -400001, Maharashtra, India
7.	Telephone & Fax No.	:	Tel. 022-22616200 / 6300 / 8787 Fax 022-22619090

Contact: 7999665955 / 7693019852 Email ID: mustafabohra@mbassociates.in

8.	Email Address	:	contactus@mangalamdrug	s.com		
9.	Website	:	mangalamdrugs.com			
10.	Name of the stock exchange where Company's Securities are Listed	:	BSE and NSE			
	N-C-1		No. of shares	% Of Total		
			No. of Shares	Issued capital		
11.	Issued Capital	:	1,58,28,248	100 %		
12.	Listed Capital	:	1,58,28,248	100 %		
13.	Held in dematerialized form in CDSL	:	56,63,010	35.77 %		
14.	Held in dematerialized form in NSDL	:	1,01,65,228	64.22 %		
15.	Physical	:	10	0.003 %		
16.	Total No. of Shares (13+14+15) : 1,58,28,248 100 %					
17.	Reason for difference if any, between (11 & 12), (11 & 16), (12 & 16)					
18.	Certifying the details of Changes in Share Capital during quarter unde consideration as per Table below: NA					

Particulars*	No of Shares	Applied / Not applied For listing	Listed on Stock Exchange (specify Name) for listing	Whether intimated to CDSL	Whether intimate d to NSDL	In- Principal approval pending for Stock Exchange (specify names)	
No Change							

^{*} Rights, Bonus, Preferential Issue, ESOP's, Amalgamation, Conversion, buy back, Capital Reduction, Forfeiture, any other (to specify).

19.	Register of Members is updated (Yes / No)	••	Yes
20.	Reference to previous quarter with regards to excess dematerialization of shares, if any	:	Not Applicable
21.	Has the company resolved	:	Not Applicable

Contact: 7999665955 / 7693019852 Email ID: mustafabohra@mbassociates.in

	the matter mentioned in point No. 20 above in the Current Quarter					
	Mention the total no. of Request, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the		Total No. of Demat Requests	No. of Requests	No. of Shares	Reasons for Delay
22.			Confirmed after 21 days	Nil	Nil	Nil
	reasons for delay		Pending for more than 21 Days	Nil	Nil	Nil
23.	Name, Telephone & Fax No. of the Compliance officer of the Company	:		1954 22616200 / 22619090	6300 / 878	37,
24.	Name, Address, Telephone, Registration No. of the Auditor	:	M. No. : A617 COP No : 2434	y Secretario , First Floor erul (E), Nea 665955 afabohra@n 27 5	es r, Haware ar Seawood nbassociate	ls Railway
25.	Appointment of common agency for share registry work if yes (name & address)	:		47 Park, L	.B.S. Marg arashtra, In O	
26.	Any other details that the auditor may like to provide (e.g., BIFR Company,	:	This report is base online from the RTA.		documents	received

F01 A/17, Haware's Centurion Mall, Sector - 19A Near Seawoods Railway Station Nerul (E), Navi Mumbai – 400706

Contact: 7999665955 / 7693019852 Email ID: mustafabohra@mbassociates.in



delisting from SE, company	
changed its name, etc.)	

Place: Mumbai

Date: 10.01.2023

M/s. Mustafa Bohra & Associates Practising Company Secretaries Mr. Mustafa Bohra



FCS: 61727 **C.P No**: 24345

Peer Review Certificate No: 2280 UDIN: A061727D002934630